Ascentage Pharma Group International vs Telix Pharmaceuticals
AAPG and TLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and TLX compare
Telix Pharmaceuticals grew revenue faster over the last twelve months (55.6% versus −41.5% for Ascentage Pharma Group International).
Telix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −0.89% compared with −216% at Ascentage Pharma Group International.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | TLX |
|---|---|---|
| Size and price | ||
| Share price | $14.62 | $9.23 |
| Change, 1 year | −55.6% | −5.9% |
| Beta (5Y) | 0.79 | 1.45 |
| Employees | 767 | 1,120 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 55.6% (better) |
| Net income growth (TTM) | – | −121% |
| EPS growth (TTM) | – | −122% |
| Profitability | ||
| Gross margin | 91.5% (better) | 53.1% |
| Operating margin | – | 3.7% |
| Net margin | −216% | −0.89% (better) |
| FCF margin | −209% | −5.3% (better) |
| Return on equity | −156% | – |
| Financial health | ||
| Debt / equity | 1.50 | – |
| Net debt / EBITDA | – | 5.17 |
| Interest coverage | – | 0.7× |
| Current ratio | 1.79 | 2.01 (better) |
| Piotroski F-score | – | 2 |
| Ownership | ||
| Held by institutions | 0.00% | 0.94% |
| Held by insiders | 13.0% | 8.3% |
| Insider net buying, 12 months | – | $1.0M |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- TLX stock overview
- TLX income statement
- TLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.